ArticleCureus2025
A Case of Metachronous Prostate Adenocarcinoma and Chromophobe Renal Cell Carcinoma in a Nigerian Male Patient: Diagnostic and Therapeutic Challenges.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate adenocarcinoma and chromophobe renal cell carcinoma (ChRCC) are two distinct urologic malignancies with different prognoses and treatment approaches. The occurrence of both tumors in the same individual is highly unusual. We describe the case of a 69-year-old man with a long-standing history of hypertension who had previously undergone prostatectomy for benign prostatic hyperplasia. In 2022, he re-presented with recurrent lower urinary tract symptoms. Biopsy confirmed acinar adenocarcinoma of the prostate (Gleason 4+3), and magnetic resonance imaging (MRI) staged the disease as T3aN0M0. He was treated with high-dose-rate (HDR) brachytherapy followed by external beam radiotherapy (EBRT). Two years later, a right renal mass was detected. While the initial histology favored oncocytoma, immunohistochemistry revealed strong cytokeratin (CK)7 expression with focal CD117 staining, confirming the eosinophilic subtype of ChRCC. This case illustrates the importance of thorough histopathologic work-up of renal lesions, the diagnostic value of immunohistochemistry, and the need for careful follow-up in patients with complex urologic histories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.